Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
Submitted 30 September 2002 ; accepted in final form 29 August 2003
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
mitogen-activated protein kinase; diabetes; kidney
Diabetic nephropathy is characterized by hypertrophy of both glomerular and tubular elements (12). Recent studies suggest that hypertrophy may lead to glomerulosclerosis and tubulointerstitial fibrosis by increasing synthesis and accumulation of extracellular matrix (23). Transforming growth factor- (TGF-
) is thought to mediate these pathological processes. Thus TGF-
mRNA and protein levels are increased in kidneys of diabetic mice, and neutralizing anti-TGF-
antibody inhibited whole kidney and glomerular hypertrophy (18, 24).
Although tubular pathology is an important component of diabetic nephropathy, available data are scarce on MAPKs in tubular cells in the diabetic state. In the present study, therefore, we examined the expression and activation of MAPKs in kidneys from diabetic rats. We also investigated the role of ERK and p38 in high-glucose-induced cellular hypertrophy and TGF- induction in LLC-PK1 cells, a porcine proximal tubular cell line, under high-glucose conditions.
![]() |
METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Induction of diabetes. Male Sprague-Dawley rats, weighing 180 g, were injected with 60 mg/kg streptozotocin (60 mg/ml in 0.01 M citric acid, 0.09% saline, pH 4) by tail vein. Rats were killed 3 wk after the injection. Rats matched for age and weight at the time of streptozotocin administration served as controls. Two diabetic rats were treated with a daily injection of insulin (Novolin U, Novo Nordisk Pharma). At death, blood was drawn from the abdominal aorta for determination of nonfasting plasma glucose by the glucose oxidase method. Kidneys were harvested and fixed with neutral buffered formalin.
Immunohistochemistry. After fixation, kidneys were embedded in paraffin. Immunohistochemical staining was performed on serial sections 3-µm thick, using the enzyme-labeled antibody method. Paraffin sections were deparaffinized and rehydrated. Endogenous peroxidase activity was quenched by incubating sections in 0.3% H2O2/methanol for 15 min. To unmask antigens, slides were boiled at 100°C for 10 min in 10% citrate buffer (pH 6.0)/methanol. Sections were incubated with antibodies against ERK (dilution 1:20), p38 (1:100), JNK (1:20), P-ERK (1:200), P-p38 (1:20), P-JNK (1:200), TGF- (1:10), or WT1 (1:50). The incubation time was 60 min at room temperature or overnight at 4°C. After being incubated with secondary antibody at a concentration of 1:100, immunoreaction products were developed using 3,3'-diaminobenzidine as the chromogen, with standardized development times. Sections were then counterstained with methyl green. Positive controls (brain for ERK and JNK, and bone marrow for p38) were run simultaneously. Negative controls included adding saturating titers of antigen (for ERK), omitting the primary antibody or substituting of the primary antibody with rabbit serum.
Cell culture. LLC-PK1 cells were purchased from the American Type Culture Collection (Rockville, MD). Cells were grown in medium 199 containing 0.5% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin supplemented with 5.5 mM glucose (normal glucose) or 25 mM glucose (high glucose). In control experiments, mannitol was added to normal-glucose medium to bring total osmolality to values equivalent to high-glucose medium. In the experiments to inhibit ERK or p38, cells were incubated with high glucose containing 5 µM PD-98059 or 5 µM SB-203580. Media were replaced every day. The cultures were maintained at 37°C in a humidified atmosphere of 95% O2-5% CO2.
Immunoblot analysis. After 24 to 72 h of culture, cells were washed with cold PBS and lysed in solubilization buffer containing 20 mM HEPES (pH 7.2), 1% Triton X-100, 10% glycerol, 20 mM sodium fluoride, 1 mM sodium orthovanadate, 1 mM PMSF, 10 µg/ml aprotinin, and 10 µg/ml leupeptin. Insoluble material was removed by centrifugation (10,500 g, 10 min). The protein content in cell lysates was measured with a DC protein assay (Bio-Rad Laboratories, Tokyo, Japan). Lysates were resolved by SDS-PAGE and transferred to PVDF membranes (Immobilon, Millipore, Bedford, MA). Nonspecific binding sites were blocked in TBS buffer (10 mM Tris·HCl, pH 7.4, 0.15 M NaCl) containing 5% skim milk overnight at 4°C or for 1 h at 25°C. Antibodies were added to TBS containing 0.1% Tween 20 in saturating titers and incubated with mixing for 2 h at 25°C. Bound antibodies were detected using the ECL Western blotting system (Amersham, Arlington Heights, IL). Blots were scanned and quantitatively analyzed by NIH Image software.
[3H]leucine incorporation. Cells were subcultured in a 24-well dish at a density of 1 x 104/ml. After 24 h, cells were incubated with normal or high-glucose media in the presence or absence of SB-203580 or PD-98059 with daily exchange. After 48 h, cells were pulsed with 1 µCi [3H]leucine. After further incubation for 24 h, cells were washed with ice-cold PBS and 5% trichloroacetic acid, solubilized in 0.5 N NaOH, and counted by a liquid scintillation counter.
Measurement of cell protein and cell number. Cells were cultured in a 24-well dish under normal- or high-glucose media in the presence or absence of SB-203580 or PD-98059. After 72 h, cells were washed with ice-cold PBS and either trypsinized for counting cell number or solubilized in 0.5 N NaOH for protein content determination. Cell number was counted using a hemocytometer.
Measurement of cell protein and DNA. Cells were trypsinized and pelleted at 1,500 g for 5 min. Each pellet was resuspended in 1 ml buffer (50 mM Na2PO4, pH 7.4), and cells were lysed on ice by repeated passage through a 27-gauge needle. The lysate was aliquoted for protein and DNA determination. DNA was measured using the fluorescent compound bisbenzimide H-33258 fluorochrome.
Statistical analysis. The results are expressed as means ± SE. Statistical analysis was performed with ANOVA followed by multiple comparisons as appropriate. Statistical significance was determined as P < 0.05.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
ERK and phosphorylated ERK. ERK was expressed in distal tubules and collecting ducts, and phosphorylated ERK was detected in occasional distal tubules and collecting ducts of control and diabetic kidneys (Fig. 1, A-E). Stronger and more frequent immunostaining for phosphorylated ERK was observed in diabetic kidneys compared with controls. Insulin treatment abrogated the upregulation of phosphorylated ERK. In glomeruli, podocytes of both control and diabetic kidneys stained positive for ERK. Phosphorylated ERK was not detected in glomeruli.
|
p38 and phosphorylated p38. No immunostaining for p38 or phosphorylated p38 was observed in control kidneys (Fig. 1, F-I). In the diabetic kidney, p38 and phosphorylated p38 were detected in distal tubules, collecting ducts, and occasional proximal tubules with weaker intensity. In glomeruli, p38 was detected in podocytes of diabetic kidneys, and phosphorylated p38 was also faintly positive. Again, insulin treatment inhibited the upregulation of p38 and phosphorylated p38.
JNK and phosphorylated JNK. JNK localized to distal tubules, collecting ducts, and occasional proximal tubules, and phosphorylated JNK was detected in distal tubules and collecting ducts of control and diabetic kidneys (Fig. 1, J-N). There was no difference in JNK or phosphorylated JNK expression between control and diabetic kidneys. Podocytes of both control and diabetic kidneys stained weakly positive for JNK but were negative for phosphorylated JNK.
TGF-. TGF-
was not detected in control kidneys (Fig. 1, O and P). In the diabetic kidney, TGF-
was expressed strongly in distal tubules, collecting ducts, and moderately in proximal tubules. Thus the tubular localization of TGF-
coincided with that of p38 and phosphorylated p38. Insulin treatment completely inhibited the high-glucose-induced TGF-
expression.
Cell culture studies. We next investigated the role of activated ERK and p38 in renal tubular cells cultured under high-glucose conditions. Because proximal tubular cells are the major contributor to diabetic kidney enlargement, LLC-K1 cells were used. We cultured cells in normal- or high-glucose media for 24 to 72 h.
ERK and p38 are activated in LLC-PK1 cells cultured under high glucose. Activation of MAPKs was detected by Western blot analysis using phospho-specific antibodies. Phosphorylated ERK1 and ERK2 were elevated twofold in cells cultured under high glucose compared with control cells at 24 h (Fig. 2). Both ERK1 and ERK2 remained activated at 72 h. Of note, phosphorylated ERK was increased at 72 h under normal glucose compared with that at 24 h, probably due to autocrine/paracrine action of growth factors secreted by the cell. In a similar manner to ERK, p38 was phosphorylated at 24 h and high levels were sustained up to 72 h (Fig. 3). Total MAPK protein levels were unaltered by high glucose throughout the course.
|
|
High glucose-induced activation of ERK and p38 is osmolality independent. Both ERK and p38 were phosphorylated at 48 h under high-glucose conditions confirming that their activation is sustained throughout the 72-h period (Fig. 4). To investigate whether high-glucose-induced activation of ERK and p38 in LLC-PK1 cells is induced by hyperosmolality, we examined the effect of mannitol with the same osmolality as high glucose. Although incubation of cells with high glucose for 48 h activated ERK and p38, incubation with mannitol had no effect on either of the MAPKs. These results demonstrate that activation of ERK and p38 by high glucose is not due to the osmotic effect.
|
ERK and p38 mediate high-glucose-induced increases in protein content, [3H] leucine incorporation, and the protein- to-DNA ratio. We next examined the role of activated ERK and p38 in high-glucose-induced hypertrophy in LLC-PK1 cells. In agreement with a previous report (4), treatment of LLC-PK1 cells with high glucose for 72 h caused a 1.9-fold increase in total protein content (P < 0.05; Fig. 5A). Coincubation with MEK inhibitor 5 µM PD-98059 or p38 inhibitor 5 µM SB-203580 completely reversed the high-glucose-induced increase in protein content. Similarly, treatment with high glucose for 72 h caused a 1.4-fold increase in [3H]leucine incorporation (P < 0.05; Fig. 5B). In the presence of either PD-98059 or SB-203580, the high-glucose-induced increase in [3H]leucine incorporation was abolished. Although cell number tended to be lower in high-glucose-treated cells compared with control cells, there was no significant difference (Fig. 5C). PD-98059 or SB-203580 did not affect the cell number of high-glucosetreated cells. Cell hypertrophy was assessed more specifically by measuring the protein-to-DNA ratio (Fig. 5D). PD-98059, SB-203580, or both had no effect on the baseline protein-to- DNA ratio. The protein-to-DNA ratio increased under highglucose conditions, which was partially inhibited by PD-98059 or SB-203580. Coincubation with both PD-98059 and SB-203580 completely abolished the high-glucose-induced increase in the protein-to-DNA ratio. Altogether, these results demonstrate that the high-glucose-induced cellular hypertrophy is independently mediated by ERK and p38.
|
ERK and p38 mediate high-glucose-induced TGF- protein expression. Because high-glucose-induced hypertrophy in proximal tubular cells has been suggested to be mediated by TGF-
(4), we next examined the role of ERK and p38 in highglucose-induced TGF-
expression. TGF-
protein was detected predominantly as a 25-kDa dimer. As shown in Fig. 6, treatment with high glucose for 72 h increased TGF-
expression. The addition of PD-98059 or SB-203580 abolished the high-glucose-induced increase in TGF-
protein, indicating that high-glucose-induced TGF-
expression is ERK and p38 dependent.
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Tubules of streptozotocin-induced diabetic rats showed increased staining for p38, phosphorylated p38, and phosphorylated ERK. Most remarkably, p38 and phosphorylated p38 were detected only in the diabetic kidney. The absence of p38 expression in the control kidney is in accord with our previous study (14). Thus p38 was detected predominantly in the fetal kidney, suggesting its role in kidney development. In the diabetic kidney, p38 and phosphorylated p38 were found in all segments of the tubules. ERK, on the other hand, was expressed by distal tubules and collecting ducts of both control and diabetic kidneys. Phosphorylated ERK was detected in distal tubules and collecting ducts and stained more intensely in diabetic kidneys than controls. TGF- protein was detected in distal tubules, collecting ducts, and to a lesser extent in proximal tubules of the diabetic kidney. Thus the localization of TGF-
coincides with that of p38, suggesting a role of p38 in the induction of TGF-
.
We further investigated the role of activated ERK and p38 using cultured cells. We studied a proximal tubular cell line (LLC-PK1) because proximal tubular cells contribute a large part of the kidney enlargement seen in diabetes. Also, the in vitro effect of high glucose has been well characterized in proximal tubular cells. Although the activation of MAPKs by high glucose has previously been demonstrated in various cell types, the functional role of activated MAPKs in the diabetic milieu is not completely understood. We demonstrated that both ERK and p38 are necessary for high-glucose-induced cellular hypertrophy and TGF- expression in LLC-PK1 cells. Tubular cells cultured under high-glucose conditions have been shown to undergo hypertrophy and to increase collagen production (27). These changes are thought to be mediated by TGF-
. Thus expression of TGF-
mRNA and bioactivity were reported to be increased by high glucose, and neutralizing anti-TGF-
antibodies attenuated the effect of high glucose (17). Our data demonstrated that the inhibition of ERK or p38 abolished the high-glucose-induced hypertrophy, as defined by increased protein content, stimulation of protein synthesis, and the protein-to-DNA ratio. Notably, the effects of MEK inhibitor PD-98059 and p38 inhibitor SB-203580 on cellular hypertrophy were additive, indicating that ERK and p38 mediate the effect of high glucose through parallel pathways. We further demonstrated that PD-98059 or SB-203580 inhibited highglucose-induced TGF-
expression. Thus ERK or p38 may mediate cellular hypertrophy by inducing TGF-
expression. In agreement with our results, Isono et al. (9) demonstrated that ERK mediated TGF-
expression in mesangial cells. Also, Weigert et al. (22) recently showed that high-glucose-induced activation of TGF-
promoter was mediated by activating protein-1 through p38 in mesangial cells. An alternative, not mutually exclusive, explanation points to the possibility that PD-98059 or SB-203580 may inhibit TGF-
signaling. TGF-
has been suggested to activate both ERK and p38. Thus Hayashida et al. (6) demonstrated that TGF-
activated ERK and that ERK mediated collagen expression in mesangial cells. In LLC-PK1 cells, TGF-
-activating kinase-1 (TAK1), a downstream kinase of TGF-
, has been shown to activate p38, and TAK1/p38 pathway mediated the growth-inhibitory effects of TGF-
(19). Of note, Zhang et al. (26) recently reported that high-glucose-stimulated angiotensinogen gene expression was mediated by p38. Because high-glucose-induced hypertrophy in renal tubule cells was blocked by angiotensin-converting enzyme inhibitors (4), p38 might mediate hypertrophy, in part, by inducing angiotensinogen.
The upregulation of p38, phosphorylated p38, phosphorylated ERK, and TGF- was most intense in distal tubules and collecting ducts. Previous studies demonstrated that high glucose along with TGF-
caused hypertrophy in a distal tubular cell line, Mardin-Darby canine kidney cells (25). Furthermore, a study by Rasch et al. (13, 16) demonstrated that distal tubules also resulted in cellular hypertrophy and hyperplasia in streptozotocin-induced diabetes. Thus activated ERK or p38 may also play a role in diabetic alteration of distal tubules.
The mechanism of cellular hypertrophy has recently been elucidated at the level of the cell cycle. Cells undergo hypertrophy when they arrest at the late G1 phase (15, 23). Highglucose-induced hypertrophy is considered to be caused by mitogen-induced movement of cells into the G1 phase followed by arrest at the G1/S (7). Recent studies demonstrated functional interactions between Ras/Raf/ERK cascade and G1 phase cell-cycle progression and suggested that ERK is essential for the stimulation of cyclin D1 (11). Activated ERK in the diabetic state, therefore, may stimulate cells to enter the G1 phase. Failure of cells to progress into S phase occurs when cyclin E kinase is not fully activated. Huang and Preisig (7) suggested that the inhibition of cell cycle progression in proximal tubular cells harvested from diabetic rats might be mediated by TGF-. Previous studies showed that anti-TGF-
-neutralizing antibody attenuated the glucose-induced inhibition of cell proliferation (17). Collectively, ERK and p38 may be involved in high-glucose-induced arrest at G1/S boundary by inducing TGF-
and/or mediating TGF-
signaling.
Previous studies by Ishida et al. (8) and Gruden et al. (3) demonstrated that stretch-induced fibronectin and TGF- production in mesangial cells were mediated by ERK and p38, respectively. Mechanical stretch is an in vitro model for glomerular hypertension seen in diabetes. Their results underscore the importance of ERK and p38 in diabetic kidney disease. Of note, the present study demonstrated that p38 and ERK were immunohistochemically detected in podocytes. Although currently no in vitro data are available, our observation may suggest a possible role of podocytes in the pathogenesis of diabetic nephropathy.
In conclusion, the present study in renal tubular cells, together with previous results in glomeruli and mesangial cells, suggests that ERK and p38 may play pivotal roles in the development and progression of diabetic nephropathy. These molecules may be a potential target for the treatment of the disease.
![]() |
ACKNOWLEDGMENTS |
---|
This study was supported by grants from the Ministry of Education, Science, and Culture, Japan (10670757, 12770610, 12770401, 13770404), and the Pharmacia-Upjohn Fund for Growth and Development Research.
![]() |
FOOTNOTES |
---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|